Press Release


Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
Sep 23, 2020 08:24 JST
The CHMP's positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalization) by expanding the approved age range from 12 years and above to 4 years and above, and for primary generalized tonic-clonic seizures (PGTCS) from 12 years and above to 7 years and above.
More info..

Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 23, 2020 08:10 JST
Results from LEAP-004 (Abstract #LBA44) and LEAP-005 (Abstract #LBA41) were accepted as late-breaking abstracts and are being presented in proffered paper presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
More info..

Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sep 18, 2020 10:29 JST
Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
More info..

Eisai Establishes Pharma Sales Subsidiary in Vietnam
Sep 17, 2020 08:59 JST
Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam, which will be named Eisai Vietnam Co., Ltd., Eisai Vietnam is a wholly-owned subsidiary of Eisai.
More info..

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
Sep 11, 2020 09:41 JST
Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020.
More info..

Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Sep 07, 2020 08:02 JST
Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020.
More info..

Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Aug 25, 2020 11:55 JST
Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago.
More info..

Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
Aug 25, 2020 09:30 JST
Eisai Co., Ltd. announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGOTM CIV) will be given at the 34th annual meeting of the Associated Professional Sleep Societies (SLEEP 2020), to be held virtually from August 27 to 30, 2020.
More info..

Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
Jul 31, 2020 08:31 JST
In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
More info..

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
Jul 22, 2020 16:04 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020.
More info..

Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
Jul 20, 2020 11:36 JST
Allm Inc., Tokyo Medical and Dental University and Eisai Co., Ltd. announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED).
More info..

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 14, 2020 08:20 JST
The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe.
More info..

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Jul 13, 2020 10:47 JST
Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization.
More info..

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Jul 09, 2020 11:20 JST
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease.
More info..

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 09, 2020 11:11 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA.
More info..

Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Jul 08, 2020 13:33 JST
Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health.
More info..

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
Jul 08, 2020 13:16 JST
Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma.
More info..

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
Jul 06, 2020 08:33 JST
Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.
More info..

Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
Jul 06, 2020 08:05 JST
Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020.
More info..

Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
Jul 01, 2020 13:02 JST
The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19.
More info..

Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
Jun 25, 2020 10:47 JST
Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").
More info..

Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa
Jun 10, 2020 12:49 JST
Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below.
More info..

Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
Jun 04, 2020 10:43 JST
Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM", which Eisai has launched in Japan, is to be expanded in the fixed-rate membership beauty salon "Attina", which is operated by Youforio Co., Ltd.
More info..

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
Jun 02, 2020 10:05 JST
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020.
More info..

AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 14:54 JST
AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (HS) after the first 4 weeks of treatment.
More info..

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 10:31 JST
The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively.
More info..

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18, 2020 12:33 JST
Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020.
More info..

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14, 2020 08:22 JST
Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020.
More info..

Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
Apr 27, 2020 16:26 JST
This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector.
More info..

Latest Release


More Latest Release >>